The Unblinded Coordinator
A CRC on a double-blind, placebo-controlled trial of an anti-inflammatory for chronic pain is responsible for scheduling, drug accountability, and entering participant-reported pain scores into the EDC system. During a drug accountability check, she opens a sealed randomization envelope to reconcile a discrepancy in kit numbers and learns that participant 014 is on placebo. Participant 014 has reported no improvement after 8 weeks and has told the CRC, 'I'm sure I'm on the real drug, it's just slow - I want to keep going.' The CRC also knows participant 014's pain scores are a primary endpoint. The CRC has not told anyone she opened the envelope. The protocol requires that anyone unblinded to a participant's assignment be documented and that the participant's data be flagged for the blinded analysis. The PI is on vacation for two weeks, and the next monitoring visit is in ten days.
1. What has gone wrong, and what is the CRC's immediate obligation?
Read the worked answer
What went wrong:
- The CRC opened a randomization envelope outside any protocol-authorized unblinding procedure. If reconciliation required unblinding, the protocol likely specifies who may unblind and how; a CRC doing it unilaterally is a deviation.
- She is now unblinded to a participant whose primary endpoint she is responsible for entering. That creates a bias risk to the data.
- She has not disclosed the unblinding, which compounds the problem - an undocumented unblinding is worse than a documented one, because no one can correct for it.
Immediate obligation:
- Disclose. The CRC must tell the PI (or, if truly unreachable, the sponsor's clinical monitor or the site's research compliance office) that she opened the envelope and is unblinded. The two-week vacation does not justify silence; there are escalation paths.
- Stop entering that participant's endpoint data until the PI or sponsor decides how to handle it. Continuing to enter blinded-endpoint data while unblinded is the specific harm to avoid.
- Document the date, reason, and circumstances of the unblinding in the source record - contemporaneously, not reconstructed later.
- Preserve the envelope and kit documentation as evidence of what happened.
She should not conceal the unblinding to 'avoid trouble' before the monitoring visit - disclosure before the monitor arrives is far better than discovery during it.
2. How should the participant's data and continued participation be handled, and how do you respond to her belief that she is on the real drug?
Read the worked answer
Data handling: The protocol's requirement - flag the participant's data for the blinded analysis - exists precisely for this situation. The CRC should not decide the analysis fate herself; she should ensure the PI and sponsor know the participant was unblinded so they can apply the pre-specified handling. Options typically include flagging, sensitivity analysis, or exclusion from certain analyses, per the SAP. The CRC's job is to make the fact visible and follow the pre-specified rule, not to improvise.
Continued participation: Unblinding the coordinator does not automatically require withdrawing the participant, but it must be assessed. The key questions: can endpoint data still be collected and entered without bias (e.g., by a blinded staff member)? Is there any risk to the participant's safety or welfare from continuing? The PI/sponsor should make this call; the CRC should raise it rather than assume.
Responding to her belief: The CRC must not confirm or deny her assignment. Telling her she is on placebo would unblind her, damage the trial, and potentially harm her (loss of hope, distress). The appropriate response is neutral: acknowledge her experience, note that neither of you knows the assignment, and route her concerns about lack of improvement to the PI as a clinical and safety matter. Her statement 'I'm sure I'm on the real drug' is not something the CRC should correct - it is something to document and escalate clinically.
3. What should happen before and during the monitoring visit, and what systemic fix would you propose?
Read the worked answer
Before the visit: The CRC should ensure the unblinding is disclosed and documented, and that the PI (or designee) is aware before the monitor arrives. Going into a monitoring visit with a known, undisclosed unblinding is a much worse position than presenting it proactively. The CRC should prepare a factual account: what was found, why the envelope was opened, when, and what was done afterward.
During the visit: Be transparent with the monitor. Answer questions factually; do not minimize. The monitor will assess whether the unblinding affected data integrity and whether the protocol's flagging requirement was met. The CRC should not attempt to 'fix' records in advance.
Systemic fix: The root cause is that a CRC with endpoint-entry duties had both the access and the perceived need to unblind for a reconciliation task. Fixes:
- Separate the roles - drug accountability and envelope access should sit with someone who does not enter blinded endpoint data, or reconciliation should be handled by the pharmacist or an unblinded monitor.
- A written unblinding procedure with a named approver and a log, so that any unblinding is authorized and recorded at the time.
- Emergency-envelope controls - tamper-evident seals, a sign-out log, and a requirement to notify the sponsor immediately if opened.
- Training on why unblinding creates a data-integrity risk, not just a paperwork step.
These address the cause rather than just the individual event.